GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Modalis Therapeutics Corp (TSE:4883) » Definitions » Cash Receipts from Fees and Commissions

Modalis Therapeutics (TSE:4883) Cash Receipts from Fees and Commissions


View and export this data going back to 2020. Start your Free Trial

What is Modalis Therapeutics Cash Receipts from Fees and Commissions?

Cash Receipts from Fees and Commissions only applicable to companies reporting Cash Flow from Operations in direct method.


Modalis Therapeutics (TSE:4883) Business Description

Industry
Traded in Other Exchanges
N/A
Address
16-5 Nihombashi-Kabuto-cho, Chuo-ku, Tokyo, JPN, 103-0026
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.